Food and Drug Administration responses to the challenges of AIDS. NLM AIDSLINE Important note: Information in this article was accurate in 1983. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Food and Drug Administration responses to the challenges of AIDS.

Public Health Rep. 1983 Jul-Aug;98(4):320-3. Unique Identifier : AIDSLINE MED/83300800
Meyer HM Jr

Abstract: Rarely has a public health issue emerged that has had impact on so many aspects of the responsibilities of the Food and Drug Administration. In a curious sense, the emergence of AIDS as a national problem has been timely. Only a few years ago, the scientific basis did not exist for performing studies of the immunology and pathogenesis of the syndrome--studies that should be helpful in directing therapeutic and preventive measures. Many of the techniques for studying AIDS and for manufacturing products to treat it involve modern technology. Research and policy actions that FDA has initiated have been designed to ensure as fully as possible the safety and effectiveness of regulated products that are relevant to AIDS and to apply new technology to this important public health problem.
Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY/*ETIOLOGY/ IMMUNOLOGY Containment of Biohazards/METHODS Factor VIII/ANALYSIS Hemophilia/MORTALITY Human Interferons/THERAPEUTIC USE Lymphokines/THERAPEUTIC USE Plasma/ANALYSIS Syndrome United States *United States Food and Drug Administration Virus Diseases/ETIOLOGY/IMMUNOLOGY JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/drugtherapy/KWDetiology/immunologycontainmentofbiohazards/methodsfactorviii/analysishemophilia/mortalityhumaninterferons/therapeuticuselymphokines/therapeuticuseplasma/analysissyndromeunitedstatesKWDunitedstatesfoodanddrugadministrationvirusdiseases/etiology/immunologyjournalarticle
831230
M83C0028

Copyright © 1983 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1983. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1983. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .